Recent research reveals that bowel cancer diagnosed before age 50 may differ significantly from cases diagnosed later in life. This study examined key differences in tumor characteristics, genetics, and survival rates among younger patients.

“Early-onset bowel cancer has distinct features influencing treatment approaches,” observed researchers who analyzed data from 1,691 Australians, focusing on those whose cancer had spread solely to the liver.

The study, published in The Medical Journal of Australia, identifies variations in the disease that might impact treatment strategies. In Australia, bowel cancer rates are among the highest globally, particularly affecting younger adults.

Key Finding: Biological Differences

Comparisons between younger and older patients reveal several significant distinctions. Younger patients diagnosed before 50 tend to be women, have left-sided bowel tumors, and carry specific genetic mutations. Furthermore, they often have a survival advantage with spread to the liver compared to older patients.

Professor Savio George Barreto from Flinders University noted, “The findings reinforce our belief in the distinct biology and behavior of early-onset cancers.”

Genetic Factors and Treatment Decisions

Genetics plays a crucial role in treatment outcomes. The study found tumors with BRAF or KRAS mutations linked to poorer results across all ages. These findings emphasize the importance of genetic testing for personalized treatment strategies.

A new study aspect identified NRAS mutations as influential in guiding treatment decisions. Genetic insights offer potential for individualizing care, considering tumor characteristics and genetic profiles.

Treatment Approaches for Younger Patients

The research explored treatment impact on outcomes. Young patients undergoing liver tumor surgery followed by drug treatment often experienced better results. Treatment sequencing showed differences based on age demographics.

Barreto explained, “Upfront curative surgery for early-onset patients provides greater survival benefit.” Conversely, chemotherapy first may benefit older patients with certain cancer characteristics.

Although observational, the study’s real-world clinical data underscores the need for further research, aiming to address rising bowel cancer rates among younger adults.

Supporting Younger Survivors

Supporting younger patients post-treatment remains a priority. Their needs differ from older patient groups traditionally targeted by survivorship programs.

“Identifying epigenetic biomarkers can advance early targeted screening if the PELICan hypothesis holds,” Barreto suggested, emphasizing proactive risk identification.

The research supports distinguishing early-onset bowel cancer from its late-onset counterpart due to unique tumor characteristics and genetic patterns. Understanding these differences aids in personalized treatment planning, offering improved patient care.

The researchers concluded, “Bowel cancer diagnosed before age 50 is not simply the same disease occurring earlier.”

Reference: Savio G. Barreto et al. Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning. The Medical Journal of Australia. DOI: 10.5694/mja2.70266